Broadening the scope of image-guided radiotherapy (IGRT)

Acta Oncologica

Volumn 47, Issue 7, 2008, Pages 1193-1200

  Greco, Carlo ^a   Ling, C Clifton ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; REVIEW;

DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY, COMPUTER-ASSISTED;

EID: 51049088405     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802241956     Document Type: Review

References (87)

1. Ling CC, Yorke E, Fuks Z. From IMRT to IGRT: Frontier-land or neverland? Radiother Oncol 2006;78:119-22.
2. Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: A systematic review for the American College of Physicians. Ann Intern Med 2007;146:516-26.
3. Miller A, Markowitz S, Manowitz A, Miller JA. Lung cancer screening using low-dose high-resolution CT scanning in a high-risk workforce: 3500 nuclear fuel workers in three US states. Chest 2004;125:152S-153S.
4. Mazzone P, Obuchowski N, Mekhail T, Meziane M, Ahmad M. Lung cancer screening: Is it time for a change in policy? Cleve Clin J Med 2007;74:441-8.
5. Torres C, Szomstein S, Wexner SD. Virtual colonoscopy in colorectal cancer screening. Surg Innov 2007;14:27-34.
6. Olsen AH, Njor SH, Lynge E. Estimating the benefits of mammography screening: The impact of study design. Epidemiology 2007;18:487-92.
7. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:1014-20.
8. Mehta PS, Harrison LB. Function and organ preservation in adult cancers of the head and neck. Expert Rev Anticancer Ther 2007;7:361-71.
9. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536-44.
10. Veronesi U, Zurrida S. Breast conservation: Current results and future perspectives at the European Institute of Oncology. Int J Cancer 2007;120:1381-6.
11. Schaefer JF, Schlemmer HP. Total-body MR-imaging in oncology. Eur Radiol 2006;16:2000-15.
12. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: Experience on a 32-channel system. Invest Radiol 2005;40:743-53.
13. Shiau MC, Bonavita J, Naidich DP. Adenocarcinoma of the lung: Current concepts in radiologic diagnosis and management. Curr Opin Pulm Med 2007;13:261-6.
14. Wood KA, Hoskin PJ, Saunders MI. Positron emission tomography in oncology: A review. Clin Oncol (R Coll Radiol) 2007;19:237-55.
15. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983-95.
16. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153-67.
17. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63:2723-7.
18. Artemov D, Bhujwalla ZM, Bulte JW. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 2004;5:485-94.
19. Collingridge DR, Glaser M, Osman S, Barthel H, Hutchinson OC, Luthra SK, et al. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003;89:1327-33.
20. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: A review of recent clinical studies. Radiother Oncol 1991;20(Suppl 1):13-9.
21. Haubner R. Alphavbeta3-integrin imaging: A new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33(Suppl 1):54-63.
22. Schoder H, Yeung HW, Larson SM. CT in PET/CT: Essential features of interpretation. J Nucl Med 2005;46:1249-51.
23. Branstetter BF, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S, et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 2005;235:580-6.
24. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
25. Mah K, Caldwell CB, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-50.
26. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [(11)C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: Results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007.
27. Greco C, Cascini GL, Tamburrini O. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? Prostate Cancer Prostatic Dis 2008.
28. Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: An initial analysis. BJU Int 2007;99:786-93.
29. Sherouse GW, Bourland JD, Reynolds K, McMurry HL, Mitchell TP, Chaney EL. Virtual simulation in the clinical setting: Some practical considerations. Int J Radiat Oncol Biol Phys 1990;19:1059-65.
30. Fiorino C, Reni M, Bolognesi A, Cattaneo GM, Calandrino R. Intra- and inter-observer variability in contouring prostate and seminal vesicles: Implications for conformal treatment planning. Radiother Oncol 1998;47:285-92.
31. Foppiano F, Fiorino C, Frezza G, Greco C, Valdagni R. The impact of contouring uncertainty on rectal 3D dose-volume data: Results of a dummy run in a multicenter trial (AIR-OPROS01-02). Int J Radiat Oncol Biol Phys 2003;57:573-9.
32. Geets X, Daisne JF, Arcangeli S, Coche E, De PM, Duprez T, et al. Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: Comparison between CT-scan and MRI. Radiother Oncol 2005;77:25-31.
33. Van de SJ, Linthout N, de MJ, Vinh-Hung V, Claassens C, Noppen M, et al. Definition of gross tumor volume in lung cancer: Inter-observer variability. Radiother Oncol 2002;62:37-49.
34. Senan S, Chapet O, Lagerwaard FJ, Ten Haken RK. Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol 2004;14:308-14.
35. Parker CC, Damyanovich A, Haycocks T, Haider M, Bayley A, Catton CN. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intraprostatic fiducial markers for computed tomography coregistration. Radiother Oncol 2003;66:217-24.
36. Voroney JP, Brock KK, Eccles C, Haider M, Dawson LA. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. Int J Radiat Oncol Biol Phys 2006;66:780-91.
37. Khoo VS, Joon DL. New developments in MRI for target volume delineation in radiotherapy. Br J Radiol 2006;79(Spec No 1):S2-S15.
38. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
39. Raaijmakers AJ, Hardemark B, Raaymakers BW, Raaijmakers CP, Lagendijk JJ. Dose optimization for the MRI-accelerator: IMRT in the presence of a magnetic field. Phys Med Biol 2007;52:7045-54.
40. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: A new standard? J Nucl Med 2007;48(Suppl 1):68S-77S.
41. Greco C, Rosenzweig K, Cascini GL, Tamburrini O. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 2007.
42. van Baardwijk A., Baumert BG, Bosmans G, van KM, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006;32:245-60.
43. Ashamalla H, Guirgius A, Bieniek E, Rafla S, Evola A, Goswami G, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys 2007.
44. van BA, Baumert BG, Bosmans G, van KM, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006;32:245-60.
45. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005;63:1016-23.
46. Fox JL, Rengan R, O'Meara W, Yorke E, Erdi Y, Nehmeh S, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiat Oncol Biol Phys 2005;62:70-5.
47. Madani I, Duthoy W, Derie C, De GW, Boterberg T, Saerens M, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:126-35.
48. Paulino AC, Koshy M, Howell R, Schuster D, Davis LW. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and- neck cancer. Int J Radiat Oncol Biol Phys 2005;61:1385-92.
49. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100.
50. Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys 2004;59:4-5.
51. Gregoire V. Is there any future in radiotherapy planning without the use of PET: Unraveling the myth. Radiother Oncol 2004;73:261-3.
52. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: A new standard? J Nucl Med 2007;48(Suppl 1):68S-77S.
53. Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El N, I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: Is a single standardized uptake value threshold approach appropriate? J Nucl Med 2006;47:1808-12.
54. Black QC, Grills IS, Kestin LL, Wong CY, Wong JW, Martinez AA, et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 2004;60:1272-82.
55. Davis JB, Reiner B, Huser M, Burger C, Szekely G, Ciernik IF. Assessment of 18F PET signals for automatic target volume definition in radiotherapy treatment planning. Radiother Oncol 2006;80:43-50.
56. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 2005;46:1342-8.
57. Low DA, Nystrom M, Kalinin E, Parikh P, Dempsey JF, Bradley JD, et al. A method for the reconstruction of four-dimensional synchronized CT scans acquired during free breathing. Med Phys 2003;30:1254-63.
58. Nehmeh SA, Erdi YE, Pan T, Yorke E, Mageras GS, Rosenzweig KE, et al. Quantitation of respiratory motion during 4D-PET/CTacquisition. Med Phys 2004;31:1333-8.
59. Ford EC, Mageras GS, Yorke E, Ling CC. Respiration-correlated spiral CT: A method of measuring respiratory-induced anatomic motion for radiation treatment planning. Med Phys 2003;30:88-97.
60. Yorke E, Rosenzweig KE, Wagman R, Mageras GS. Interfractional anatomic variation in patients treated with respiration-gated radiotherapy. J Appl Clin Med Phys 2005;6:19-32.
61. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
62. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
63. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005;62:545-53.
64. Wen B, Burgman P, Zanzonico P, O'donoghue J, Cai S, Finn R, et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 2004;31:1530-8.
65. Zanzonico P, Cai S. Comparative microPET tumor imaging of F18-labeled fluoro-deoxyglucose (FDG) and fluoro-misonidazole (FMiso) using animal-specific positioning molds. J Nucl Med 2003;44(Suppl):116.
66. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-28.
67. Zanzonico P, Campa J, Polycarpe-Holman D, Forster G, Finn R, Larson S, et al. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol 2006;33:65-70.
68. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetylbis( N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-502.
69. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys 2008;70:2-13.
70. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42.
71. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on (18)F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008;70:1219-28.
72. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 2005;92:1599-610.
73. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006;8:262-77.
74. Stein J, Mohan R, Wang XH, Bortfeld T, Wu Q, Preiser K, et al. Number and orientations of beams in intensity-modulated radiation treatments. Med Phys 1997;24:149-60.
75. Cao D, Holmes TW, Afghan MK, Shepard DM. Comparison of plan quality provided by intensity-modulated arc therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 2007;69:240-50.
76. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 2002;54.921-7.
77. Bentzen SM. Dose painting and theragnostic imaging: Towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology. Cancer Treat Res 2008;139:41-62.
78. Vanderstraeten B, Duthoy W, De GW, De NW, Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006;79:249-58.
79. Chang J, Mageras GS, Yorke E, De AF, Sillanpaa J, Rosenzweig KE, et al. Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography. Int J Radiat Oncol Biol Phys 2007;67:1548-58.
80. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004;59:1295-300.
81. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-6.
82. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92.
83. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301-10.
84. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754-8.
85. Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, et al. Diffusion MRI: A new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002;1:336-43.
86. Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003;21:1094-100.
87. Dirix P, De KF, Vandecaveye V, Stroobants S, Hermans R, Nuyts S. Diffusion-weighted magnetic resonance imaging to evaluate major salivary gland function before and after radiotherapy. Int J Radiat Oncol Biol Phys 2008.